Pre-Exposure Prophylaxis
Long-acting injectable PrEP could modestly decrease HIV incidence among MSM
Replacing daily oral PrEP with long-acting injectable PrEP could modestly decrease HIV incidence among men who have sex with men, according to a modeling study published in The Journal of Infectious Diseases.
Truvada payments totaled more than $2B in 2018
Third-party and out-of-pocket payments for a 30-day supply of Truvada for HIV pre-exposure prophylaxis added up to $2.08 billion in 2018, data show.
HIV not linked to COVID-19 risk, other highlights from AIDS 2020
W. David Hardy, MD, scientific and medical consultant, and adjunct professor of medicine in the division of infectious diseases at Johns Hopkins University School of Medicine, shared some important take-aways for clinicians from this year’s International AIDS Conference with Healio.
Blood donations by people taking drugs to treat, prevent HIV could be ‘cause for concern’
Blood donations from people on antiretroviral therapy to treat HIV or pre-exposure prophylaxis to prevent HIV infection could increase risk for HIV transfusion transmission if tests cannot detect the virus in the donations, study results showed.
One-third of HIV PrEP users discontinued medication while sheltering in place
A recent survey showed that approximately 33% of patients in the United States discontinued PrEP while sheltering in place during the COVID-19 pandemic.
Intervention promotes PrEP uptake, adherence in Kenyan adolescent girls and young women
A three-pronged intervention promoted HIV pre-exposure prophylaxis (PrEP) uptake and adherence among adolescent girls and young women in Kenya who face significant barriers to care, researchers reported.
Trial ‘definitively’ shows superiority of long-acting injectable PrEP
A PrEP regimen containing long-acting injectable cabotegravir provided superior protection against HIV infection compared with daily oral PrEP, updated study findings confirmed.
How can clinicians help patients overcome stigma associated with HIV PrEP?
PrEP has been available in the U.S. since 2012. Studies have shown that, when taken daily, it is effective at preventing HIV infection. However, stigma remains a major barrier to more widespread use.
Q&A: Evaluating adolescents for HIV PrEP
The authors of a recent MMWR report noted several “unique considerations” that clinicians face when evaluating adolescent patients for HIV pre-exposure prophylaxis, or PrEP, including legal issues of consent and the potential need for more support to promote adherence to the medication.
‘Substantial misinformation’ affects PrEP uptake among American MSM
The majority of urban American men who have sex with men, or MSM, who are at risk for HIV do not use pre-exposure prophylaxis treatment, or PrEP — suggesting a need for more interventions that increase awareness and uptake of PrEP in this group, according to findings from CROI 2020.